Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
November 04, 2020 08:35 ET | Equillium
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 04:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
May 05, 2020 08:03 ET | aTyr Pharma, Inc.
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
November 26, 2019 16:07 ET | Equillium
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
November 06, 2019 08:05 ET | Equillium
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Removing Obstacles from the Modern Infertility Patient’s Journey
April 24, 2019 09:00 ET | Progyny
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- RMA of New York, a Manhattan-based fertility clinic and Progyny, the leading fertility benefits company, presented original research on the modern...
ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
November 27, 2018 04:47 ET | ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium    
December 21, 2017 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech to Present Research Abstracts at the 6th Pharmaceutical Sciences World Congress
May 23, 2017 09:00 ET | AXIM Biotechnologies, Inc
NEW YORK, May 23, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Lekhram Changoer,...
Cellular Biomedicine Group Inc. Logo
Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting
May 19, 2017 08:28 ET | Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...